Characterization of the effect of naltrexone/bupropion on body composition
Authors' conclusion
NB-induced weight loss is associated with significant reductions in total percent fat mass, increase in total percent lean mass, and change in lean-to-fat mass ratio, in comparison to placebo. Larger studies are needed to further elucidate the clinical significance of these changes and impact of a potentially healthier metabolism.
Study context
- Population
- Subgroup of COR-I phase 3 trial participants with body composition assessed by DXA; comparable baseline age, BMI, sex
- Participants
- 82 participants
- Comparison
- Naltrexone/bupropion vs placebo
- Naltrexone/bupropion (NB)n = 56
- Placebon = 26reference
- Primary endpoint
- Changes in total, lean and fat mass by DXA
- Follow-up
- Baseline to week 52
Methodological detailssubgroup with DXA, placebo-controlled, phase 3
- Subgroup with DXA
- Placebo-controlled
- Phase 3
Primary result
As reported in the abstract
Change in total mass · week 52
| Group | Value | Fat mass change | Lean mass change |
|---|---|---|---|
| NB | −7.8% | −12.9% | −4.1% |
| Placebo | −2.8% | −4.8% | −1.4% |
Value
NB−7.8%
Placebo−2.8%
Fat mass change
NB−12.9%
Placebo−4.8%
Lean mass change
NB−4.1%
Placebo−1.4%
Further findings
| Outcome | NB | Placebo | P value |
|---|---|---|---|
| Adjusted change in lean-to-fat mass ratio · week 52Adjusted for baseline covariates | 0.069 | −0.056 | P < 0.05 |
Original publication
Characterization of the effect of naltrexone/bupropion on body composition. Diabetes Obes Metab. Published 10 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →